YU24391A - Poboljšana meningokokna polisaharid kon-jugovana vakcina - Google Patents

Poboljšana meningokokna polisaharid kon-jugovana vakcina

Info

Publication number
YU24391A
YU24391A YU24391A YU24391A YU24391A YU 24391 A YU24391 A YU 24391A YU 24391 A YU24391 A YU 24391A YU 24391 A YU24391 A YU 24391A YU 24391 A YU24391 A YU 24391A
Authority
YU
Yugoslavia
Prior art keywords
group
polysaccharide
antibodies
gbmp
coli
Prior art date
Application number
YU24391A
Other languages
English (en)
Inventor
H.J. Jennings
F. Michon
Original Assignee
National Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council filed Critical National Research Council
Priority to SI9110243A priority Critical patent/SI20008B/sl
Priority to HRP-243/91A priority patent/HRP920872A2/hr
Publication of YU24391A publication Critical patent/YU24391A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

neisseria menigitidis grupa B polisaharid (GBMP) modifikovan tako da ima ostatak sialinske kiseline N-acetil grupa zamenjen sa N-acil grupama, pokazuje naglašen imuno odgovor uz to. Dodatno, minimizirana je indukcija antitela koja ukršteno reaguju sa nemodifikovanom grupom B meningococcalnim i E.coli kl kapsularnim polisaharidom i drugim ćelijskim tkivima koja imaju zajednički epitop. Konjugovanje modifikovanog polisaharida sa fiziološki prihvatljivim proteinom takvim kao tetanusni toksoid indukuje proizvodnju specifičnih zaštitnih antitela sa zanemarljivim nivoima GBMP-ukršteno reaktivnim antitelima čime se ostvaruje zaštita protiv infekcija izazvanih pomoću grupe B meningococci i E.coli Kl.
YU24391A 1989-12-14 1990-12-14 Poboljšana meningokokna polisaharid kon-jugovana vakcina YU24391A (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI9110243A SI20008B (en) 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine
HRP-243/91A HRP920872A2 (en) 1989-12-14 1992-10-02 Improved meningococcal polysaccharide conjugate vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14

Publications (1)

Publication Number Publication Date
YU24391A true YU24391A (sh) 1995-12-04

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
YU24391A YU24391A (sh) 1989-12-14 1990-12-14 Poboljšana meningokokna polisaharid kon-jugovana vakcina

Country Status (30)

Country Link
US (3) US5576002A (sh)
EP (1) EP0504202B1 (sh)
JP (1) JP2637845B2 (sh)
KR (1) KR0158436B1 (sh)
CN (4) CN1049223C (sh)
AR (1) AR243934A1 (sh)
AT (1) ATE121947T1 (sh)
AU (1) AU641715B2 (sh)
BR (1) BR9007917A (sh)
CA (1) CA2071811C (sh)
CZ (1) CZ283530B6 (sh)
DE (1) DE69019164T2 (sh)
DK (1) DK0504202T3 (sh)
ES (1) ES2071288T3 (sh)
FI (2) FI104539B (sh)
HR (1) HRP920872A2 (sh)
HU (2) HU218146B (sh)
IE (1) IE68414B1 (sh)
IL (1) IL96676A (sh)
IN (1) IN171747B (sh)
NO (2) NO305275B1 (sh)
NZ (1) NZ236471A (sh)
PH (1) PH30305A (sh)
PL (2) PL166035B1 (sh)
RO (1) RO111416B1 (sh)
RU (1) RU2105568C1 (sh)
SI (1) SI20008B (sh)
WO (1) WO1991008772A1 (sh)
YU (1) YU24391A (sh)
ZA (1) ZA9010065B (sh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
NZ248766A (en) * 1992-09-24 1996-11-26 Ca Nat Research Council Capsular polysaccharide-protein conjugate vaccine against group b streptococcus type ii or v
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
CZ390297A3 (cs) * 1995-06-07 1998-05-13 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
WO1998008874A1 (en) 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
EP0994723A1 (en) 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
AU9120898A (en) 1997-08-27 1999-03-16 Chiron Corporation Molecular mimetics of meningococcal b epitopes
AU754256C (en) 1997-12-23 2004-05-20 Pfizer Ireland Pharmaceuticals Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
EP1109576B1 (en) * 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
CN1306956C (zh) 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
PT1490409E (pt) * 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
RU2333223C2 (ru) * 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
KR20070060069A (ko) 2004-06-23 2007-06-12 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 다당류 유도체 및 면역반응의 유도에서의 용도
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
EP2170391B1 (en) * 2007-06-20 2017-01-18 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
IL267733B2 (en) * 2017-01-31 2023-10-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신

Also Published As

Publication number Publication date
US5902586A (en) 1999-05-11
DK0504202T3 (da) 1995-10-02
AU6898791A (en) 1991-07-18
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
HU218146B (hu) 2000-06-28
IN171747B (sh) 1992-12-26
IL96676A (en) 1996-09-12
NO922316L (no) 1992-08-14
RO111416B1 (ro) 1996-10-31
HRP920872A2 (en) 1997-06-30
NO305275B1 (no) 1999-05-03
CN1100428A (zh) 1995-03-22
CN1055541A (zh) 1991-10-23
PL166659B1 (pl) 1995-06-30
JP2637845B2 (ja) 1997-08-06
CZ283530B6 (cs) 1998-04-15
CN1036522C (zh) 1997-11-26
NO922316D0 (no) 1992-06-12
ES2071288T3 (es) 1995-06-16
CN1096516A (zh) 1994-12-21
CA2071811C (en) 2003-11-04
RU2105568C1 (ru) 1998-02-27
FI19991917A (fi) 1999-09-09
PL166035B1 (pl) 1995-03-31
NZ236471A (en) 1992-10-28
IE904513A1 (en) 1991-06-19
IE68414B1 (en) 1996-06-12
WO1991008772A1 (en) 1991-06-27
CA2071811A1 (en) 1991-06-15
NO973311L (no) 1992-08-14
JPH05505392A (ja) 1993-08-12
US5576002A (en) 1996-11-19
CN1049223C (zh) 2000-02-09
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
DE69019164T2 (de) 1995-09-07
AU641715B2 (en) 1993-09-30
CZ628490A3 (en) 1997-12-17
EP0504202A1 (en) 1992-09-23
PL288271A1 (en) 1991-12-16
IL96676A0 (en) 1991-09-16
CN1100656A (zh) 1995-03-29
CN1072506C (zh) 2001-10-10
EP0504202B1 (en) 1995-05-03
US5683699A (en) 1997-11-04
SI20008A (sl) 2000-02-29
NO307835B1 (no) 2000-06-05
ZA9010065B (en) 1992-02-26
PH30305A (en) 1997-02-20
HU9201966D0 (en) 1992-10-28
DE69019164D1 (de) 1995-06-08
FI104539B (fi) 2000-02-29
ATE121947T1 (de) 1995-05-15
BR9007917A (pt) 1992-10-20
FI922737A0 (fi) 1992-06-12
AR243934A1 (es) 1993-09-30
KR0158436B1 (ko) 1998-12-01

Similar Documents

Publication Publication Date Title
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
Danve et al. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals
IS3753A7 (is) Endurbætt aðferð og samsetning bóluefnis
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
MC2178A1 (fr) Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
HK1021145A1 (en) Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
NZ291262A (en) E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
ATE212233T1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
KR920002790A (ko) 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
Cryz Jr et al. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
US7754227B2 (en) Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
KR920703097A (ko) 스트렙토코커스 b군에 대한 백신 접합체
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
Banknieder et al. Protection Against Meningococcal Challenge Afforded Mice After Immunization with Typhoid-Paratyphoid Vaccine USP
Grozdanova et al. Design, synthesis and determination of physical and chemical characteristics of glycoconjugates as model for oligosaccharide vaccines against vibrio cholerae